Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700332 · ClinicalTrials.gov registry record · Phase 2
PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by Hoag Memorial Hospital Presbyterian.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 1
- Study location
NCT04700332: Recruiting Phase 2 study of Prostate Cancer, sponsored by Hoag Memorial Hospital Presbyterian.
NCT04700332 is a Phase 2 study of Prostate Cancer that is actively recruiting participants, run by Hoag Memorial Hospital Presbyterian. The registered enrollment target is 184 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04700332, a Phase 2 study of Prostate Cancer, is actively recruiting participants, sponsored by Hoag Memorial Hospital Presbyterian.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 1
- Study location
Study Summary
The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate cancer cells. PyL PET/CT may provide improved evaluation of clinically significant metastases in patients with prostate cancer.
Conditions Studied
Interventions
- DRUG DCFPyL PET/CT
Study Locations (1)
California
- Hoag Memorial Hospital Presbyterian - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04700332
The ClinicalTrials.gov registry entry for NCT04700332 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (70% lower). The listed sponsor is Hoag Memorial Hospital Presbyterian, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which DCFPyL PET/CT is the first listed.
NCT04700332 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04700332 about?
NCT04700332 is a clinical study titled "PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer". The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be suboptimal. PyL is a novel PET tracer designed to detect prostate specific membrane antigen (PSMA) expressed on prostate ca...
What is the current status of trial NCT04700332?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2021-02-01. Estimated completion is 2022-12-15.
What conditions does trial NCT04700332 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT04700332?
The interventions under investigation include: DCFPyL PET/CT (DRUG).
Who is sponsoring clinical trial NCT04700332?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04700332 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.